Anthony Bergmann, M.B.A., currently holds the position of Chief Financial Officer at Capricor Therapeutics Inc., a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment of rare diseases. With an extensive background in finance and a strong track record in the life sciences industry, Bergmann has played a pivotal role in steering Capricor's financial strategy and growth. Before joining Capricor Therapeutics, Bergmann held several key positions in the biotechnology sector. He previously served as the Chief Financial Officer at a privately-held biopharmaceutical company, where he was instrumental in securing significant funding and guiding the company through multiple rounds of financing. Bergmann's expertise in financial planning, investor relations, and strategic partnerships has been crucial in driving Capricor's mission to bring innovative therapies to patients with unmet medical needs. As CFO at Capricor Therapeutics, Bergmann oversees all aspects of the company's financial operations, including budgeting, forecasting, and financial reporting. His strategic vision and leadership have been essential in navigating the complex financial landscape of the biotechnology industry. Bergmann's dedication to advancing Capricor's pipeline of groundbreaking therapies, combined with his financial acumen, has positioned the company for continued success and growth in the years ahead.